Streetbeat News

Regulatory

AMZN

The Federal Trade Commission (FTC) has claimed that Amazon's Project Nessie has cost American households over $1 billion, according to a complaint cited by Reuters.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 2:58 pm

VIRI

Virios Therapeutics has received FDA guidance to progress IMC-1 to Phase 3 study for Fibromyalgia. Several life science companies are reviewing Phase 2 data and proposed Phase 3 program for a potential partnership. Virios has also submitted briefing materials to the FDA for a proposed investigational new drug application for IMC-2 as a treatment for Long-COVID. The company has filed for intellectual property protection for IMC-2 as treatment for LC and Alzheimer’s disease, which if granted, provides coverage to at least 2043. The company expects to have capital to support operations into Q3 of 2024.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 2:58 pm

AMZN

The Federal Trade Commission (FTC) complaint against Amazon (AMZN) in U.S. Federal Court has been made public with fewer redactions, according to Reuters citing the court docket.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 2:53 pm

SPY

VGK

Fox News' Chad Pergram reports that Johnson has stated that funding for Ukraine will come soon and will be paired with border security.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 2:40 pm

CPRX

Catalyst Pharmaceuticals has received notification from the United States Patent and Trademark Office (USPTO) that two additional patents covering FIRDAPSE® (amifampridine) Tablets 10 mg will be granted within the next two months. These patents are associated with the unique bioavailability of FIRDAPSE under fasting and fed conditions of dosing. FIRDAPSE is the only approved treatment available in the U.S. for Lambert-Eaton myasthenic syndrome.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 2:38 pm

PRGS

Progress Software (NASDAQ:PRGS), a producer of enterprise software products, has been highlighted in a report by The Bear Cave due to a significant data breach involving its secure file transfer service, MOVEit. The breach, which is believed to affect the privacy of millions of Americans and compromise important government agencies, was discovered on May 30, 2023. The U.S. Cybersecurity & Infrastructure Security Agency (CISA) and the FBI have released an advisory on the issue, and the U.S. Department of State has offered a reward of up to $10 million for information linking the breach to a foreign government.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 2:32 pm

NVDA

Nvidia's stock value dropped by 5% following news of a potential cancellation of $5 billion worth of chip orders to China due to new U.S. government restrictions. However, the stock has shown resilience, rebounding by 7% from its Tuesday low. The stock has increased by 184% for the year. The $400 level has proven to be a strong support, with potential for the stock to reach the $500 resistance level.

Portfolio Pulse from Zaheer Anwari

November 02, 2023 | 2:31 pm

EIS

SPY

VGK

Democratic Leader Schumer announced that the U.S. Senate will not consider the House funding bill on Israel, but will work on its own bipartisan emergency aid package that includes aid to Israel and Ukraine.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 2:23 pm

EIS

SPY

USO

A top Israeli general has signaled a willingness to allow fuel to enter Gaza if hospitals run out, according to Reuters. The news may impact the stocks of EIS (iShares MSCI Israel ETF), SPY (SPDR S&P 500 ETF Trust), and USO (United States Oil Fund).

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 2:12 pm

MLYS

Mineralys Therapeutics (NASDAQ:MLYS) presented a new post-hoc analysis from the Target-HTN Phase 2 trial of lorundrostat, a treatment for uncontrolled or treatment-resistant hypertension. The analysis supports obesity-associated dysregulated aldosterone as an endotype predictive of enhanced response to lorundrostat treatment. The ongoing Advance-HTN trial will further characterize hypertensive endotype for enhanced response to lorundrostat treatment.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 2:05 pm